Popular anti-obesity drugs continue to show cardiovascular benefits beyond weight loss, according to several new papers ...

At AHA, Phase 2 results from Eli Lilly and Silence Therapeutics are seen as signs of a "major new path" of cardiovascular ...

Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...

The combination of sacubitril and valsartan reduces the cardiotoxicity related to anthracycline chemotherapy drugs, according ...

Excess cholesterol is known to form artery-clogging plaques that can lead to stroke, arterial disease, heart attack, and more, making it the focus of many heart health campaigns.

New research suggests that a procedure now regarded as Plan B when patients have episodes of rapid heartbeat after a ...

A little more than a month after AstraZeneca jumped into the fray with the purchase of a rival heart drug candidate, Eli ...

More than half of all American adults, almost 137 million people, could be candidates for the blockbuster GLP-1 drug ...

An experimental oral drug called muvalaplin shows promise in reducing the cholesterol linked to heart disease in a study.

Hypochondria can, in extreme cases, leave people unable to hold down a job or make it impossible for them to leave the house, ...

Inflammation is generally the indication of a health problem. But new research suggests we think differently about inflammation, especially in relation to heart disease and the prevention of atheroscl ...